PBM Reform Under Medicare-for-All

Most people have never heard of a pharmacy benefit manager, and yet PBMs quietly decide what a huge share of Americans pay at the pharmacy counter. That's the strange part of this story. An industry most patients can't name has more influence over their drug costs than almost anyone they can.

A PBM sits between drug manufacturers, insurance plans, and pharmacies. It negotiates rebates with manufacturers, decides which drugs an insurance plan will cover, and sets how much a pharmacy gets paid for filling a prescription. In theory, that middleman role should push prices down through negotiating leverage. In practice, critics have argued for years that PBMs kept a share of those savings rather than passing them fully to patients.

What Actually Changed in February 2026

Congress passed real reform this year, not just another round of hearings. The Consolidated Appropriations Act of 2026, signed in early February, requires PBMs to remit essentially all rebates and manufacturer payments back to health plans rather than keeping a cut, a change usually called "delinking" because it separates PBM compensation from the price of the drug itself.

The law also brought in an "any willing pharmacy" provision, meaning Medicare drug plans will eventually have to let any pharmacy that meets standard contract terms join their network, which should help independent pharmacies that previously got squeezed out. Flat, disclosed administrative fees replace the old system where a PBM's income was tied to how expensive a drug was, an incentive structure that never made much sense from a patient's perspective.

Here's the catch worth being upfront about: most of these provisions don't take effect until 2028 or 2029. The law passed, but the actual changes to what you pay at the pharmacy counter are still years away, and the full financial impact remains to be seen.

Where Medicare-for-All Goes Further

Medicare-for-All proposals, the various single-payer bills that have circulated in Congress over the years, take a fundamentally different approach to this problem. Rather than regulating the PBM layer, most versions would functionally remove it, replacing the current multi-payer, PBM-mediated system with direct government negotiation and administration of drug benefits.

In clinical practice, this distinction is often missed because both ideas get lumped together as "fixing drug prices." They're not the same lever. PBM reform tries to make the existing system more transparent and accountable. Medicare-for-All tries to replace the system PBMs operate within altogether. You can support one without supporting the other, and plenty of policy analysts do exactly that.

The Case Made For Going Further

Supporters of a single-payer approach argue that PBM reform, even done well, still leaves a fragmented system with multiple insurers, multiple formularies, and multiple layers of administrative cost. Their argument is that as long as private insurers and their PBM partners are negotiating separately, drug companies retain leverage that a single national buyer, negotiating on behalf of the entire country, would not have to concede.

They also point to countries with single-payer or centralized negotiation systems that report lower per-capita drug spending, though comparing health systems across countries involves enough structural differences that direct cost comparisons are contested rather than settled.

The Case Made Against Going Further

Critics of Medicare-for-All, including many who support PBM reform on its own, raise different concerns. They argue that eliminating the current insurance and PBM structure would be enormously disruptive to existing coverage arrangements, provider contracts, and the broader health insurance workforce, disruption that carries its own costs and risks.

Some also argue that recently enacted PBM reform hasn't had time to show results yet, since most provisions phase in through 2028 and 2029, and that judging the current system as failed before those reforms take effect skips a step. Others raise concerns about the tax and budgetary implications of a fully government-run system, an area where estimates vary widely depending on the assumptions used.

What This Means If You're Just Trying to Follow the News

If you see "PBM reform" in a headline right now, it almost always refers to the 2026 legislation already signed into law, not a future single-payer proposal. If you see "Medicare-for-All," that's a separate, ongoing policy debate that hasn't passed Congress and isn't tied to the PBM reforms already enacted.

Whether you'll notice a difference at the pharmacy counter depends heavily on which provisions eventually take effect and how strictly they're enforced, something worth watching over the next two to three years rather than expecting overnight.